A recent review suggested that the use of opioids during immune checkpoint inhibitor (ICI) treatment has an adverse effect on patient prognosis. This artic
Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.
Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC.
AbstractBackground. Anomalous origin of the left coronary artery (LCA) from the pulmonary artery (PA) (ALCAPA) is a rare congenital abnormality. We present
Technological innovations in genomics and related fields have facilitated large sequencing efforts, supported new biological discoveries in cancer, and spawned an era of liquid biopsy…
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses Part 2 of the DESTINY-Gastric03 trial (NCT04379596), which evaluated trastuzumab deruxtecan (T-DXd) with…
Hereditary transthyretin amyloidosis with polyneuropathy is caused by mutations in the TTR gene. Chao et al. show that mutant TTR disrupts the blood–nerve
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and…
China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our…
